What Peak Bio does

Peak Bio is a clinical-stage biopharmaceutical company developing therapies for inflammatory and oncology indications. The company operates two distinct technical platforms: (1) PHP-303, a fifth-generation, orally bioavailable small molecule inhibitor of neutrophil elastase being positioned for Phase II development in Alpha-1 Antitrypsin Deficiency (AATD) and Acute Respiratory Distress Syndrome (ARDS), with reported approximately 90% neutrophil elastase inhibition at doses of 5mg or higher; and (2) the proprietary TORPEDO™ ADC platform, which couples antibodies to novel immunostimulatory payloads — PH-1 (a Thailanstatin-based spliceosome modulator), PH-5 (a DNA mismatch repair interferer), and PH-6 (an immune suppression payload) — that are designed to differ from industry-standard tubulin/DNA-targeted ADC payloads, with the goal of reducing off-target toxicities such as neutropenia and peripheral neuropathy while generating immune memory. The lead ADC candidate targets Trop2-expressing solid tumors and is in IND-enabling preclinical stages, with an 18-24 month stated path to first-in-human studies.

The company was founded in 2015 as pH Pharma by Hoyoung Huh, MD, PhD and rebranded to Peak Bio, Inc. in January 2021. It became a publicly traded company in April 2022 via a business combination with Ignyte Acquisition Corp., a SPAC, supported by a $25 million PIPE investment. The company currently trades on OTCQB under the ticker PKBO rather than the originally anticipated NASDAQ listing; firmographic data also indicates a delisted status. Headquartered in Pleasanton, California with research operations in the Bay Area and G&A infrastructure in South Florida, Peak Bio employs 11-50 people. The business model is pre-revenue drug development; the company does not yet have commercialized products, distribution channels, or pricing and would rely on traditional pharmaceutical commercialization or partnership/out-licensing upon regulatory approval of any pipeline candidate. The company has not disclosed revenue, and the financial figures shown in the financials section are inconsistent with a 11-50 employee pre-revenue clinical-stage biotech funded by a single $25M PIPE round and are treated as data artifacts.

Name

Peak Bio

Legal name

Peak Bio, Inc.

Website

https://peak-bio.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Peak Bio is a clinical-stage biopharmaceutical company developing PHP-303, a neutrophil elastase inhibitor for AATD and ARDS, and a proprietary TORPEDO ADC platform for solid tumors. Pre-revenue and publicly traded on OTCQB:PKBO following a 2022 SPAC merger.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Drug Development

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industries

Alpha-1 Antitrypsin (AAT) Therapies (HLAIAHAD), Lead Optimization & Preclinical Candidate Selection (HLAIALAB), Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA), Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)

Keywords

• Antibody-drug conjugates
• Neutrophil elastase inhibitors
• Oncology therapeutics
• Inflammatory disease drugs
• Small molecule inhibitors

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Marketing channels4 records

Core offering

Peak Bio is a clinical-stage biopharmaceutical company developing innovative small-molecule and antibody-drug conjugate (ADC) therapies for oncology and inflammatory diseases. Its lead clinical asset is PHP-303, an oral once-daily fifth-generation neutrophil elastase inhibitor in Phase II-ready status for Alpha-1 Antitrypsin Deficiency (AATD) and Acute Respiratory Distress Syndrome (ARDS). Its second core offering is the proprietary TORPEDO ADC platform, which generates ADCs with novel immunostimulatory payloads (PH-1 spliceosome modulator, PH-5 DNA mismatch repair interference, PH-6 immune suppression), with lead Trop2-targeted candidate M2.9 PH1 ADC progressing toward IND.

Product overview

Peak Bio is a clinical-stage biotech company developing a portfolio of innovative therapies for oncology and inflammation. The company's core products include PHP-303, a Phase II-ready oral neutrophil elastase inhibitor for Alpha-1 Antitrypsin Deficiency (AATD) and ARDS, and a differentiated ADC pipeline built on the proprietary TORPEDO™ platform. The TORPEDO™ platform generates novel ADCs using immunostimulatory payloads (PH-1, PH-5, PH-6) that differ from industry-standard tubulin/DNA targeted payloads, offering potential for improved safety/efficacy profiles and immune memory. Lead ADC candidates include M2.9 PH1 ADC targeting Trop2-expressing solid tumors and M5 PH1 ADC targeting an unnamed solid tumor antigen.

Differentiator

Problem solved

Functional benefit

Products and services

• PHP-303 PHP-303 is a novel, oral, once-daily, potent, selective small-molecule inhibitor of Neutrophil Elastase (NE) being developed as a fifth-generation Phase II-ready therapeutic for Alpha-1 Antitrypsin Deficiency (AATD) and Acute Respiratory Distress Syndrome (ARDS), addressing limitations of current weekly IV augmentation therapies.
• TORPEDO ADC Platform Peak Bio's proprietary ADC platform technology enabling the development of antibody-drug conjugates with novel immunostimulatory payloads (spliceosome modulators and DNA mismatch repair interferers), differentiated from industry-standard tubulin/DNA targeted payloads.
• M2.9 PH1 ADC A novel ADC targeting RNA splicing of Trop2-expressing solid tumors, utilizing the PH-1 spliceosome modulator payload. IND-ready candidate with 18-24 month path to First-in-Human (FIH) studies.
• M5 PH1 ADC A novel ADC targeting RNA splicing of an unnamed target expressed in solid tumors, utilizing the PH-1 spliceosome modulator payload from the TORPEDO platform.
• PH-1 (Thailanstatin) Toxin Payload Peak Bio's proprietary spliceosome modulator payload (Thailanstatin) that disrupts alternative splicing, deprives cancer cells of essential survival factors, causes mis-spliced protein accumulation inducing tumor cell death, and generates neoantigens recognized by immune cells.

Quantifiable outcome

• Approximately 90% NE inhibition at doses of 5mg or higher
• +4 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Mersana Therapeutics: Clinical-stage ADC company developing novel payloads and linkers for cancer therapeutics. Highly comparable to Peak Bio as a small-cap, pre-commercial ADC specialist with proprietary payload technology targeting solid tumors.
• Bolt Biotherapeutics: Clinical-stage biotech developing immune-stimulating ADCs (ISACs) that combine antibody targeting with immunostimulatory payloads. Directly comparable to Peak Bio's TORPEDO platform, which also uses immunostimulatory payloads to engage the immune system.
• Pyxis Oncology: ADC-focused oncology company developing differentiated antibody-drug conjugates for solid tumors. Comparable to Peak Bio as a clinical-stage ADC platform company with similar target patient populations and payload innovation.
• Vertex Pharmaceuticals: Major biopharma with an active AATD program (acquired Alpine Immune Sciences and others). Comparable to Peak Bio as a competitor developing novel therapies for alpha-1 antitrypsin deficiency, the lead indication for PHP-303.

Emerging players

• ProfoundBio: Clinical-stage biotech developing next-generation ADCs with novel payloads and linkers, including Trop2-directed candidates. Closely comparable to Peak Bio's Trop2 ADC candidate in target and approach.
• Tubulis: Biotech developing differentiated ADCs with novel payload classes and stable linkers. Comparable to Peak Bio's TORPEDO platform in its focus on payload/linker innovation over target novelty.

Broad incumbents

• Daiichi Sankyo: Japanese pharma major that pioneered the DXd ADC platform and developed Trodelvy (Trop2 ADC) and Enhertu (HER2 ADC, with AstraZeneca). Sets the competitive bar for Peak Bio's Trop2 ADC candidate.
• AstraZeneca: Global biopharma co-developing and commercializing Datroway/Enhertu ADCs with Daiichi Sankyo, including a leading Trop2 ADC franchise. Comparable as a large strategic acquirer of differentiated ADC technology platforms.
• CytomX Therapeutics: Clinical-stage oncology company developing Probody-enabled ADCs and other targeted therapeutics. Comparable to Peak Bio as a platform-based ADC developer with shared leadership lineage (Peak Bio's founder was previously Chairman of CytomX).

Others

• Pliant Therapeutics: Clinical-stage biotech developing therapies for fibrotic diseases including pulmonary conditions. Comparable to Peak Bio as a small Bay Area biotech with shared leadership connections (Peak Bio's founder served as Lead Director at Pliant).

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Peak Bio